… In that model, the failure pattern was used as a continuous variable. In contrast, in … failure
at less than 12 months and those with failure after 12 months. We found that patients with failure …

… Intravesical bacillus Calmette-Guérin (BCG) is a standard conservative treatment for patients
… bladder-preserving intravesical treatments in patients with bacillus Calmette-Guérin failure …

… Patients with recurrent SBC having failure despite at least 1 prior … failure group and showed
similar responses to the non-intolerant patients, they are grouped together as 1 BCG failure …

… The definition of bacille-Calmette-Guerin (BCG) failure must be specified in the context of
previous treatments and the time interval of recurrence. Valrubicin is the only FDA approved …

… We assess the efficacy and safety of intravesical valrubicin for the treatment of carcinoma
in situ in patients with failure or recurrence after bacillus Calmette-Guerin (BCG) and who …

BACKGROUND: The efficacy of intravesical gemcitabine was evaluated compared with
repeated administration of bacille Calmette‐Guérin (BCG) after BCG failure in high‐risk, non‐…

… BCG, it protected them from acute hepatic failure (90% survival rate) … -induced fatal hepatic
failure by regulating production of … role of MIF in acute hepatic failure in mice induced by BCG …

… Concomitant carcinoma in situ was not predictive of failure of bacillus Calmette-Guérin
therapy. An independent factor for treatment failure was remaining T1 stage at second resection. …

PURPOSE: We determined whether combining low dose bacillus Calmette-Guerin (BCG)
interferon-α2B would be effective for patients in whom previous BCG failed. MATERIALS AND …

… Evaluate the efficacy and safety of valrubicin for bacillus Calmette-Guérin (BCG)–refractory
carcinoma in situ (CIS) of the bladder based on updated phase III pivotal trial efficacy data …